China News Service, February 1. According to the website of the State Food and Drug Administration, on the 1st, the 2023 National Drug Registration Management and Drug Post-Market Supervision Work Conference was held in Beijing.
The meeting summarized the work in 2022 and the past five years, analyzed the current situation and tasks, and deployed key tasks in 2023.
The meeting pointed out that as drug supervision embarks on a new journey, it is necessary to have a clear understanding of the new situation and the courage to face new challenges.
In accordance with the work idea of "emphasizing politics, strengthening supervision, ensuring safety, promoting development, and benefiting people's livelihood", we must continue to strengthen the bottom line of drug safety, deepen the reform of the drug review and approval system, improve the efficiency of drug review, approval and supervision, and effectively protect the people. Medication is safe and effective.
The meeting emphasized that in 2023, drug registration management and post-marketing supervision of drugs should achieve steady progress on the five main lines of "epidemic prevention and control, risk resolution, innovation and development, capacity improvement, and clean government construction": do a good job in the development of new coronavirus vaccines and drug services, Emergency review and approval and quality supervision work to serve and guarantee the overall situation of epidemic prevention and control; strengthen the supervision of key varieties, key links, and key areas, consolidate and expand the achievements of special rectification actions, and effectively prevent and resolve hidden safety risks; continue to deepen the reform of the review and approval system, and accelerate The market speed of urgently needed new drugs, drugs for rare diseases, and drugs for children, etc., innovate regulatory methods and means, and promote high-quality development of the industry; improve the regulatory system, promote the electronic process of drug registration acceptance, review, and approval, and promote the standardized development of the drug inspection system , improve regulatory efficiency; strengthen the building of a clean and honest government, consolidate the anti-corruption mechanism, severely punish violations of laws and disciplines, and provide a strong guarantee for solidly advancing the modernization of drug supervision with Chinese characteristics.
(China New Finance and Economics)